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Cryptosporidiosis affects humans of all ages, particularly malnourished children and those with
compromised immune systems such as HIV/AIDS. This study investigated the therapeutic effects of
acetylspiramycin and garlicin on Cryptosporidium infection in institutionalized male drug users receiving
rehabilitative treatment. Examination of stool specimens from 903 drug users via modiﬁed acid-fast
bacilli staining resulted in 172 positive cases. Among them 151 subjects consented to participate in a
randomized trial of acetylspiramycin and garlicin in four groups: acetylspiramycin plus garlicin, ace-
tylspiramycin only, garlicin only, and placebo control. The cryptosporidiosis rate was higher in younger
subjects with longer drug use history than subjects who are older with shorter history of drug use. After
two segments of treatments, 76.2% of the cases achieved negative test results, with the four groups
achieving the rates of 92.1%, 76.7%, 72.2%, and 61.8%, respectively (c2 ¼ 9.517, P ¼ 0.023). These results
indicate clinical potential of garlicin in conjunction with acetylspiramycin in treating cryptosporidiosis.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cryptosporidiosis is an emerging parasitic infection caused by
Cryptosporidium spp., and is one of the most common causes of
diarrhea in humans of all age groups in China (An et al., 2011; Feng
et al., 2012; Liu et al., 2014; Yao et al., 2014) and worldwide (Yoder
et al., 2012; Insulander et al., 2013). The 1993 outbreak of crypto-
sporidiosis in Milwaukee, Wisconsin USA in which over 400,000
people were sickened was the ﬁrst major waterborne outbreak due
to Cryptosporidium infection (Mac Kenzie et al., 1994). Since then
cryptosporidiosis has been reported regularly throughout the
world for general populations as well as those with HIV/AIDS
(Assefa et al., 2009; Bartelt et al., 2013; Uppal et al., 2014). However,
little has been reported speciﬁcally for drug users (Masarat et al.,
2012).
Cryptosporidium parasites are difﬁcult to eradicate because they(M.-Z. Huang), lincoln0221@
gqing@aliyun.com (D.-Q. Li),
g@163.com (R. Gui), chen_
Ltd on behalf of Australian Society fare resistant to many disinfectants and aren't effectively removed
by many ﬁlters. They can also survive in the environment for many
months at varying temperatures (Kothavade, 2012). Most healthy
people recover from infectionwithin 10 days to twoweeks without
medical attention. Children and people with weakened immune
systems, especially thosewith HIV/AIDS, are prone to having severe
and prolonged diarrhea, leading to malnutrition, wasting, or even
death. However, there's no reliable treatment for cryptosporidiosis
(Vandenberg et al., 2012). The most commonly-used antiparasitic
antibiotics such as paromomycin, azithromycin, and spiramycin are
only partially effective (Graczyk et al., 2011; Sinkala et al., 2011; Das
et al., 2013). Nitazoxanide, a relatively new antiparasitic drug, has
been approved for treatment of diarrhea caused by Cryptosporidium
in people with healthy immune systems, but is ineffective in
immunosuppressed individuals (Mainali et al., 2013; Yacoub et al.,
2014). Therefore new drugs against this parasite are urgently
needed.
As an extract of garlic, garlicin has been conﬁrmed to have
multiple curative effects such as antimicrobial (Tsao and Yin, 2001),
antithrombotic (Fukao et al., 2007), hypolipidemic (Asdaq, 2015)
and antitumor activities (Thomson and Ali, 2003). Lately, some
reports tested the effect of garlicin in the treatment of parasites,or Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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2013) and cryptosporidiosis. In addition, garlicin has been used as
a traditional extract of medicinal plant successfully to treat cryp-
tosporidiosis in farm animals (Kadria et al., 2015) and mice (Liu
et al., 2002a; Gaafar et al., 2012; Wang and Zhang, 2013). Several
Chinese case reports according to garlicin have shown promising
anti-Cryptosporidium effect in Infants and young children (Yang and
Ge, 1994; Shen and Ge, 1997).
Two Chinese studies (Chen and Shen, 2011; Wang and Zhang,
2014) suggested that spiramycin, a semisynthetic antibiotic rec-
ommended for treating toxoplasmosis. Spiramycin is believed to
target the apicoplast ribosome (Wang and Zhang, 2014). As one of
the macrolide antibiotics, acetylspiramycin is an acetylated deriv-
ative of spiramycin, which is better than spiramycin in oral ab-
sorption rate and stability, and primarily treats toxoplasmosis
(Maeda, 2003; Jiang et al., 2000).
This paper reports a randomized trial that investigated the
therapeutic effects of acetylspiramycin and garlicin on Cryptospo-
ridium infection in institutionalized drug users enrolled in a drug
rehab center in Changsha, Hunan China.
2. Materials and methods
2.1. Population and study subjects
Male drug users were screened for enrollment in 2012 from a
drug rehabilitation center in Changsha, Hunan China. Heroin was
used among 99% of the subjects. Upon giving written consent, each
subject was evaluated for inclusion/exclusion criteria. Procedures at
baseline included the medical history, physical examination,
collection of stool for parasite examination (including Cryptospo-
ridium), and an assessment of stool characteristics in recent two
months (frequency, consistency, presence of mucus or blood).
Diarrhea was deﬁned as at least 3 unformed stools per day. Stools
were regarded to be unformed if theywere soft (taking the shape of
the container) or watery (could be poured or soaked into a diaper).
Asymptomatic carrier of Cryptosporidium was deﬁned as normal
defecation (not more than 2 times a day, without loose or watery
stools) but Cryptosporidium spp oocysts positive.
Cases with Cryptosporidium spp oocysts positive in a duplicate
detection of stool sample within 7 days before enrollment were
eligible for enrollment in the study. Cases were excluded from the
study for the following reasons: cryptosporidiosis examination
negative the day before study drug administration; hypersensitiv-
ity to acetylspiramycin or garlicin; treatment during the 14-day
period immediately before study drug administration with any
putative anticryptosporidial agent (spiramycin, diclazuril, letra-
zuril, atovaquone, bovine colostrum, azithromycin, clarithromycin,
or octreotide).
2.2. Study design
Informed consent was obtained from all the study participants
before this study began. The research protocol was approved by the
Institutional Review Board at Xiangya School of Medicine, Central
South University. The consenting cryptosporidiosis cases were
randomized to four treatment groups under a 2x2 factorial design.
Patients in group A (n ¼ 38) received a combination of acetylspir-
amycin and garlicin; subjects in group B (n ¼ 43) received acetyl-
spiramycin only; cases in group C (n ¼ 36) received garlicin only;
and those in group D served as vehicle controls (n ¼ 34).
2.3. Test of cryptosporidiosis
Stool specimens were ﬁrst smeared into a stool membrane of2 cm in diameter. After drying, they were ﬁxed with carbine l and
stained using the modiﬁed acid-fast bacilli staining method. The
ﬁnal diagnosis of cases was made by comparing the shape and
colors of sporozoites with reference standards of positive speci-
mens that were developed previously (Huang et al., 1998), and was
veriﬁed independently by the Parasitology Department of Nanjing
Medical University (Ge and Shen, 1991).
2.4. Treatment regimens
Patients in groups A and B took 200 mg acetylspiramycin
(200 mg/100000 units, with 99.5% purity, Henan Topfond Phar-
maceutical Company, China, catalog number: 100801) 4 times daily.
Patients in groups A and C took 40 mg garlicin (with 97.8% purity,
Hubei Jin Longfu Medicine co., LTD, in China, catalog number:
110529) 4 times daily. Both drugs and placebo were orally admin-
istered in gelatin capsules. Patients in all groups were treated with
given drugs or placebo for 7 consecutive days as the ﬁrst segment,
during which no other medications were allowed. A stool sample
was collected from participants on the 7th day of treatment.
Parasitological response was assessed by examination for the
presence of oocysts of Cryptosporidium spp by microscopic exami-
nation of the modiﬁed acid fast bacilli staining. Three smears per
specimenwere evaluated. Parasitological response was recorded as
either “eradication” (no oocysts observed in either post-treatment
stool sample) or “persistence” (oocysts observed in either or both
post-treatment stool samples). If all the three parallel stool samples
examined on the 7th day were negative, the case was conﬁrmed to
be cryptosporidiosis negative and received no further treatment. If
the stool samples examined on the 7th day were positive in oocysts
of Cryptosporidium spp, cases would to be offered 7 more days of
treatment consecutively as the second segment and be evaluated
parasitological response again on the 14th day. The endpoint for
therapeutic evaluation was the cryptosporidiosis eradication
response recorded on day 14 after the start of treatment. If the
parasitological response still “persistence” on the 14th day, cases
would to be treated for another more 7 days only for consolidation
curative effect, but the treatment outcomes in this section would
not to be included in the therapeutic evaluation for the last 14 days.
2.5. Statistical analysis
Data were analyzed with the SPSS version 13.0. Chi-squared test
and trend tests (Zhu and Fung, 1996) were used to compare rates of
infection and resolution of infection. In addition, Bonferroni
correctionwas applied to multiple comparison. Analysis of variance
(ANOVA) was used to compare age and mean years of drug use
history among four groups. Furthermore, a stepwise logistic
regression of recovery rate of cryptosporidiosis was conducted to
control for potential confounding effects.
3. Results
3.1. Prevalence of Cryptosporidium infection
Of the 903 participants screened in this study, 172 (19.05%)
tested positive for cryptosporidiosis (Fig 1), in which 21 left the
rehabilitation center prior to commencement of the trial. The
remaining 151 Cryptosporidium positive individuals consented to
participate. Prevalence of cryptosporidiosis varied among different
demographic groups (Table 1).
It was highest (21.49%) among 30e39 age group followed by
those 20e29 years of age (18.29%), and it was the lowest in the 40þ
age group (10.31%). Whereas the difference between the groups of
20e29 and 30e39 years of age was not signiﬁcant (c2 ¼ 1.267,
Fig. 1. Photomicrographs of fecal smears: Oocysts of Cryptosporidium spp. in acid-fast stain (at 100 times magniﬁcation). The arrowheads indicate intact oocysts, 4e6 mm in
diameter, and round to irregular in shape.
Table 1
Cryptosporidium infection by demographic groups.
Total Infected cases (%) c2 (p-value)
Agea 20e29 350 64 (18.29) 6.701 (0.035)
30e39 456 98 (21.49)
40þ 97 10 (10.31)
Drug use historyb 0e5 years 191 31 (16.23) 3.307 (0.069)
6e10 years 514 95 (18.48)
11 and more 198 46 (23.23)
Sample total 903 172 (19.05)
a Age difference is mostly attributable to that between the groups of 20e39 and
40 þ years of age (c2 ¼ 5.382; p ¼ 0.02), but not between the groups of 20e29 and
30-29 years of age (c2 ¼ 1.267, p ¼ 0.26).
b Trend test based on a quadratic trend with the three levels (0e6 years¼ 0, 6e11
years ¼ 1, 11þ ¼ 2) of drug use history.
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more pronounced (c2 ¼ 5.382, p ¼ 0.02). Subjects with junior high
school education had the highest infection rate (21.10%), followed
by those with high school education or above (16.82%) and those
with primary school or below (15.91%). But these differences
related to education-attainment were statistically insigniﬁcant
(c2 ¼ 0.2.207, p ¼ 0.33). Variation in cryptosporidiosis also varied
across occupation. Self-employed and farmers had the highest rates
(26.23% and 25.35%, respectively), and government employee and
others were among the lowest (16.03% and 15.15%, respectively).
After dividing the cases into three drug use history groups, 5 years
or less, 6e10 years, and 11 years and more, a trend test yielded
c2 ¼ 3.307 and p-value ¼ 0.069, suggesting a strong trend of
increasing rate of cryptosporidiosis with the length of drug use.
Cryptosporidium positive drug users reported none typical
symptoms of diarrheal during the 2 months preceding study entry,
so all the participants in the therapy study were asymptomatic
Cryptosporidium carriers.3.2. Therapeutic effect of acetylspiramycin and garlicin
Subjects were randomly assigned to the four treatment groups.
There were no signiﬁcant differences in age and length of drug use
among the four treatment groups (Table 2). Compliance level was
satisfactory among subjects and no adverse events were observed.
Of those who received acetylspiramycin and garlicin (Group A)Table 2
Age and drug use history of cryptosporidiosis cases.
Acetylspiramycin þ Garlicin Acetyls
Mean age (SD) 31.13(4.68) 30.49(5
Mean years of drug use(SD) 6.60(3.11) 5.61(292.1% became negative two weeks after the treatment (Table 3). In
contrast, only 61.8% of those controls (group D) were negative at
follow-up. Among those receiving acetylspiramycin (group B) alone
or garlicin (group C) alone, 76.7% and 72.2% of subjects recovered
from cryptosporidiosis, respectively. Pairwise comparisons with
Bonferroni correction (signiﬁcance level a0 ¼ 0.007) suggests that
acetylspiramycin and garlicin combined treatment signiﬁcantly
improved recovery rate from cryptosporidiosis compared with the
control (p ¼ 0.002). The improvement was also somewhat marked
compared with that of taking acetylspiramycin (p ¼ 0.060) alone or
garlicin alone (p ¼ 0.025). To control for potential confounding
effects, a logistic regression of recovery rate of cryptosporidiosis
was conducted with adjustment for age, history of drug use, edu-
cation and occupation of the subjects, treatment was the only
signiﬁcant factor to the outcome (c2 ¼ 8.257, p < 0.05).
Table 4 gives the adjusted odds ratio of recovery from crypto-
sporidiosis for each treatment relative to the control group.
4. Discussion
The incidence of Cryptosporidium infection is estimated to be
1%e3% in general population in developed countries and 10% in
developing countries. More speciﬁcally, the incidence among those
with diarrhea is about 2.2% (range, 0.26e22%) in immunocompe-
tent persons in developed countries and 6.1% (range, 1.4e41%) in
developing countries (Guerrant, 1997). It occurs in up to 7% of
children with diarrhea in developed countries and up to 12% in
developing countries. The infection rate is estimated at 14% (range,
6e70%) among persons with AIDS and diarrhea in developed
countries and 24% (range, 8.7e48%) in developing countries
(Guerrant, 1997). Manabe et al. (1998) reported Cyptosporidium
infection rate in AIDS patients was between 10% and 15% in the
United States.
Ling et al. (2001) reported a 7% infection rate among 186 pris-
oners with diarrhea. The infection rate of 19% of institutionalized
drug users in this study is even higher than 13.6% in a cohort of HIV
positive intravenous drug users in Malaysia (Kamel et al., 1994).
Repeated and chronic use of drugs may have substantially weak-
ened these users’ immune systems, resulting in a higher rate of
infection.
Cryptosporidiosis infection rate appeared to increase with the
number of years using drugs among the subjects in this sample. Anpiramycin Garlicin Control F (p-value)
.00) 33.48(6.18) 32.25(6.90) 2.048 (0.110)
.90) 7.48(3.28) 6.50(4.17) 2.047 (0.110)
Table 3
Therapeutic effects of acetylspiramycin and garlicin.
Groups Total cases Negative cases (%) Comparison c2 (P)
A:acetylspiramycin þ garlicin 38 35 (92.11%) A vs.B 3.533 (0.060)
A vs. C 5.047 (0.025)
A vs. D 9.557 (0.002a)
B:acetylspiramycin 43 33 (76.74%) B vs. D 2.034 (0.154)
C:garlicin 36 26 (72.22%) C vs. D 0.867 (0.352)
D:control 34 21 (61.76%)
Total 151 115 (76.16%)
a Signiﬁcant difference after Bonferroni correction for multiple comparison (p < 0.007).
Table 4
Odds ratio of cryptosporidiosis recovery compared with the control group after adjusting for age, length of drug, occupation, and education.
Independent variables Coef S.E. OR(95%CI) Wald c2 p-value
Age 0.018 0.039 0.982(0.910e1.060) 0.210 0.982
History of drug use 0.094 0.060 0.911(0.809e1.025) 2.414 0.12
Education 0.159 0.241 1.172(0.730e1.881) 0.432 0.511
Occupation 0.020 0.107 1.020(0.827e1.259) 0.035 0.851
Treatment groups e e e 8.257 0.041
Acetylspiramycin þ garlicin 2.014 0.704 7.490(1.886e29.750) 8.188 0.004
Acetylspiramycin onl 0.643 0.512 1.901(0.697e5.185) 1.576 0.209
Garlicin only 0.581 0.526 1.788(0.638e5.009) 1.222 0.120
Control e e 1 e e
Overall signiﬁcance of the model: c2 ¼ 36.983, p < 0.001.
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weakened the immune systems, and led to poorer health in general.
Also, cryptosporidiosis rate was signiﬁcantly higher among those
under 40 years of age than those above 40. Given the comparable
history of drug use among different age groups, the difference in
infection rate suggests that older subjects were perhaps more
capable of generating autoimmune activities against cryptospo-
ridiosis because of their more extended exposure to
Cryptosporidium.
Cryptosporidium parvum is well well-known to be associated
with persistent diarrhea as well as adversely affects nutritional
status. Cryptosporidiosis patients often have symptoms similar to
those of enteritis, clinicians may thus fail to recognize Cryptospo-
ridium, resulting in clinical misdiagnosis of cryptosporidiosis.
When a patient with persistent diarrhea fails to respond to treat-
ment, testing for cryptosporidiosis should be conducted as quickly
as possible.
While diarrhea is common among immunocompromised peo-
ple with cryptosporidiosis, it was worth noting that all the infected
drug users in this study had no symptoms of diarrhea, and of the 15
participants who injected heroin within 2 months before enroll-
ment,10 cases exhibited symptoms of constipation. This is probably
not an uncommon phenomenon and is similar to the ﬁndings re-
ported by Ravn et a1.(1991), who found the occurrence of asymp-
tomatic carriers of Cryptosporidium to be a frequent occurrence in
exposed AIDS of Cryptosporidium infection. Although the exact
mechanism is unknown, research suggests that the use of drugs
somewhat contribute to the inhibition of bowel's peristalsis. It is
also possible that their immunological status is still normal or
slightly lower or the infective dose is too small.
Nevertheless these infected drug users acted as asymptomatic
carriers should be interpreted cautiously, since them may be a
mixture of either HIV-positive or HIV- negative. It is well recog-
nized that intravenous drug use and HIV infection are highly
correlated due to the sharing of contaminated needles and syringes
(Luo et al., 2015). Injection drug use, particularly heroin, remained a
major mode of HIV transmission in China over the past two
decades. By the end of 2009, it is estimated that 740,000(560,000e920,000) people were living with HIV/AIDS (PLHIV) in
China, of whom 32.2% were infected through injecting drug use
(Ministry of Health, UNAIDS, 2014). However, it is unavoidable that
we failed to detect the HIV status within the study population,
which is ascribed to the ethical consideration for the protection of
patient's rights of privacy. Therefore, it is critical to investigate the
prevalence of co-infection with HIV, especially among the IDUs
considered to be a high-risk population of co-infection with HIV
and Cryptosporidium.
Although there are a large number of antiparasitic antibiotics
clinically available, only few are practically used to treat crypto-
sporidiosis, including speciﬁcally paromomycin, azithromycin,
spiramycin (Graczyk et al., 2011; Sinkala et al., 2011; Das et al.,
2013) and nitazoxanide (Mainali et al., 2013). However, their ther-
apeutic effects are limited (Graczyk et al., 2011; Sinkala et al., 2011;
Mainali et al., 2013; Das et al., 2013; Yacoub et al., 2014). There are a
few studies on the anti-Cryptosporidium activities of garlicin in
China (Han, 1989; Ge et al., 2001; Chen and Shen, 2011). In Han's
study, 13 pediatric cases were treated with garlicin alone for 1e6
days. Their stool specimens were examined 2e3 times between one
week to two-month after treatment. No Cryptosporidium oocysts
were observed in these follow-up examinations. Further, none of
the negative cases relapsed after treatment (Han, 1989). In the
study of Ge et al. (2001), all of the 202 infected children became
cryptosporidiosis negative after three courses of garlicin treatment
over 21 days. However, neither study was a placebo controlled.
Thus the efﬁcacy of garlicin for treating cryptosporidiosis cannot be
ascertained given the likelihood of disinfection among healthy
persons without any treatment.
The present study investigated speciﬁcally the potential of
garlicin in treating cryptosporidiosis in conjunction with acetyl-
spiramycin. Results of this study show that 61.8% of cases in the
control group became negative without medical treatment,
whereas in the group of garlicin alone and acetylspiramycin alone
the rates are 72.2% and 76.7%, respectively. These differences sug-
gest a marked improvement in using garlicin or acetylspiramycin to
reduce and eliminate Cryptosporidium activities. Combined use of
garlicin and acetylspiramycin elevated the cure rate to an even
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in treating cryptosporidiosis either alone or in combination with
other antiparasitic antibioticis. However, the mechanisms are un-
known in the literature of garlicin's activity against Cryptosporidium
spp in conjunctionwith the use of acetyspiramycin. The production
of diallyl disulﬁde (DADS) and diallyl trisulﬁde (DATS), major
components of garlicin, may have the effect of disinfectant and
fungicide, thus endowing garlicin a killing effect to the Cryptospo-
ridium (Anthony et al., 2005). Another possible mode of action is
that garlicin could markedly enhance the phagocytosis of perito-
neal macrophage, promote the transformation of T lymphocyte,
and reinforce the activity of NK cell. Because poor immune function
of the human host is the most important opportunity for crypto-
sporidiosis, improvement of the immune function of the patients
may be the most important contributor to the efﬁcacy of garlicin in
treating Cryptosporidium infection. It remains unknown how the
synergy between garlicin and acetylspiramycin in therapy, hence
further clinical investigation is under design along this line.
Drug use appears to be a risk factor to cryptosporidiosis. Special
measures of prevention and control of cryptosporidiosis are needed
to protect drug users. It is of public health importance to control
and reduce exposure to Cryptosporidium, and it is equally important
to effectively treat infected cases to prevent the spreading of
Cryptosporidium. Because diarrhea remains a common illness
among the Chinese population and can be caused by many human
pathogens such as helminth, cryptosporidiosis is easily mis-
diagnosed among patients with diarrhea. Public awareness and
knowledge about of cryptosporidiosis and its treatment are low,
resulting in another impediment to effective prevention, control,
and treatment of cryptosporidiosis. Thus timely diagnosis and
effective treatment are critically important. This study is a part of
the effort to developing effective and accessible treatment of
cryptosporidiosis in the Chinese population.
Our study has several limitations. Firstly, the participants in our
study were asymptomatic Cryptosporidium carriers, which may
impose restrictions on treatment efﬁcacy among symptomatic pa-
tients. Additionally, we failed to detect the HIV status and the ge-
notype of Cryptosporidiumwithin the study population, which may
confound study results in assessment of efﬁcacy. So a design of trial
of treatment for HIV-related cryptosporidiosis and genotypes
should be aided by the experience gained from this trial. Important
aspects include the necessity of therapeutic evaluation stratiﬁed
based on the HIV status, genotypes, severity of diarrheal and clin-
ical end points.
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